Paclitaxel

Catalog No.S1150 Batch:S115013

Print

Technical Data

Formula

C47H51NO14
Molecular Weight 853.91 CAS No. 33069-62-4
Solubility (25°C)* In vitro DMSO 100 mg/mL (117.1 mM)
Ethanol 100 mg/mL (117.1 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 5%Tween80 90%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 2.000mg/ml (2.34mM) Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clarified DMSO stock solution to 50 μL of Tween80, mix evenly to clarify; then continue to add 900 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of this compound inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to this chemical at ultra low concentrations. Inhibition of human ECs by this compound at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, this chemical at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. In the presence of SMF, the efficient concentration of this compound on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of this chemical with or without SMF on K562 cells is correlated with DNA damage. This compound alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells.

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg this compound significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs

  • Concentrations

    0.1-100 pM

  • Incubation Time

    72 hours

  • Method

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.
Animal Study:

[4]
  • Animal Models

    Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors

  • Dosages

    20 mg/kg

  • Administration

    Administered via i.v.

References

  • https://pubmed.ncbi.nlm.nih.gov/12544254/
  • https://pubmed.ncbi.nlm.nih.gov/22447825/
  • https://pubmed.ncbi.nlm.nih.gov/22433711/
  • https://pubmed.ncbi.nlm.nih.gov/22374518/
  • https://pubmed.ncbi.nlm.nih.gov/15015572/

Customer Product Validation

<p>Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.</p>

Data from [ RSC Adv , 2011 , 1, 884-892 ]

(F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

Data from [ , , Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916 ]

Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

Data from [ , , Clin Cancer Res, 2017, 23(15):4364-4375 ]

Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

Data from [ , , ACS Appl Mater Interfaces, 2015, 7(14): 7584-98 ]

Selleck's Paclitaxel Has Been Cited by 555 Publications

Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma [ Cancer Research, March 01, 2021, 1413-1425] PubMed: 33402387
Beclin1 inhibition enhances paclitaxel-mediated cytotoxicity in breast cancer in vitro and in vivo [ International Journal of Molecular Medicine, February 01, 2019, 1866-1878] PubMed: 30720049
Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS-mutated colorectal cancer [ Therapeutic Advances in Medical Oncology, December 11, 2024, 17588359241303302] PubMed: 39282351
Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells [ Oncotarget, August 22, 2017, 76479-76491] PubMed: 29100327
Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer [ Cancer Management and Research, April 20, 2020, 2641-2651] PubMed: 32368142
CRTC2 promotes paclitaxel resistance by inducing autophagy in ovarian cancer in part via the PI3K-AKT signaling axis [ Journal of Cancer, April 09, 2023, 1011-1023] PubMed: 37151390
Activation of lysosomal iron triggers ferroptosis in cancer [ Nature, 2025, 10.1038/s41586-025-08974-4] PubMed: 40335696
CD36-mediated endocytosis of proteolysis-targeting chimeras [ Cell, 2025, S0092-8674(25)00386-1] PubMed: 40250420
Signal-induced NLRP3 phase separation initiates inflammasome activation [ Cell Res, 2025, 35(6):437-452.] PubMed: 40164768
The noncanonical function of liver-type phosphofructokinase potentiates the efficacy of HDAC inhibitors in cancer [ Signal Transduct Target Ther, 2025, 10(1):341] PubMed: 41083431

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.